These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 23575870

  • 1. Methylselenol prodrug enhances MDV3100 efficacy for treatment of castration-resistant prostate cancer.
    Zhan Y, Cao B, Qi Y, Liu S, Zhang Q, Zhou W, Xu D, Lu H, Sartor O, Kong W, Zhang H, Dong Y.
    Int J Cancer; 2013 Nov; 133(9):2225-33. PubMed ID: 23575870
    [Abstract] [Full Text] [Related]

  • 2. A novel antiandrogen, Compound 30, suppresses castration-resistant and MDV3100-resistant prostate cancer growth in vitro and in vivo.
    Kuruma H, Matsumoto H, Shiota M, Bishop J, Lamoureux F, Thomas C, Briere D, Los G, Gleave M, Fanjul A, Zoubeidi A.
    Mol Cancer Ther; 2013 May; 12(5):567-76. PubMed ID: 23493310
    [Abstract] [Full Text] [Related]

  • 3. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer.
    Hu R, Lu C, Mostaghel EA, Yegnasubramanian S, Gurel M, Tannahill C, Edwards J, Isaacs WB, Nelson PS, Bluemn E, Plymate SR, Luo J.
    Cancer Res; 2012 Jul 15; 72(14):3457-62. PubMed ID: 22710436
    [Abstract] [Full Text] [Related]

  • 4. Galectin-3 Is Implicated in Tumor Progression and Resistance to Anti-androgen Drug Through Regulation of Androgen Receptor Signaling in Prostate Cancer.
    Dondoo TO, Fukumori T, Daizumoto K, Fukawa T, Kohzuki M, Kowada M, Kusuhara Y, Mori H, Nakatsuji H, Takahashi M, Kanayama HO.
    Anticancer Res; 2017 Jan 15; 37(1):125-134. PubMed ID: 28011482
    [Abstract] [Full Text] [Related]

  • 5. Sox2 is an androgen receptor-repressed gene that promotes castration-resistant prostate cancer.
    Kregel S, Kiriluk KJ, Rosen AM, Cai Y, Reyes EE, Otto KB, Tom W, Paner GP, Szmulewitz RZ, Vander Griend DJ.
    PLoS One; 2013 Jan 15; 8(1):e53701. PubMed ID: 23326489
    [Abstract] [Full Text] [Related]

  • 6. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines.
    Li Y, Chan SC, Brand LJ, Hwang TH, Silverstein KA, Dehm SM.
    Cancer Res; 2013 Jan 15; 73(2):483-9. PubMed ID: 23117885
    [Abstract] [Full Text] [Related]

  • 7. Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen.
    Evans MJ, Smith-Jones PM, Wongvipat J, Navarro V, Kim S, Bander NH, Larson SM, Sawyers CL.
    Proc Natl Acad Sci U S A; 2011 Jun 07; 108(23):9578-82. PubMed ID: 21606347
    [Abstract] [Full Text] [Related]

  • 8. Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy.
    Cao B, Qi Y, Zhang G, Xu D, Zhan Y, Alvarez X, Guo Z, Fu X, Plymate SR, Sartor O, Zhang H, Dong Y.
    Oncotarget; 2014 Mar 30; 5(6):1646-56. PubMed ID: 24722067
    [Abstract] [Full Text] [Related]

  • 9. Cotargeting Androgen Receptor Splice Variants and mTOR Signaling Pathway for the Treatment of Castration-Resistant Prostate Cancer.
    Kato M, Banuelos CA, Imamura Y, Leung JK, Caley DP, Wang J, Mawji NR, Sadar MD.
    Clin Cancer Res; 2016 Jun 01; 22(11):2744-54. PubMed ID: 26712685
    [Abstract] [Full Text] [Related]

  • 10. Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer.
    Yu Z, Chen S, Sowalsky AG, Voznesensky OS, Mostaghel EA, Nelson PS, Cai C, Balk SP.
    Clin Cancer Res; 2014 Mar 15; 20(6):1590-600. PubMed ID: 24449822
    [Abstract] [Full Text] [Related]

  • 11. Androgen Receptor Regulation of Local Growth Hormone in Prostate Cancer Cells.
    Recouvreux MV, Wu JB, Gao AC, Zonis S, Chesnokova V, Bhowmick N, Chung LW, Melmed S.
    Endocrinology; 2017 Jul 01; 158(7):2255-2268. PubMed ID: 28444169
    [Abstract] [Full Text] [Related]

  • 12. Cotargeting Androgen Receptor and Clusterin Delays Castrate-Resistant Prostate Cancer Progression by Inhibiting Adaptive Stress Response and AR Stability.
    Matsumoto H, Yamamoto Y, Shiota M, Kuruma H, Beraldi E, Matsuyama H, Zoubeidi A, Gleave M.
    Cancer Res; 2013 Aug 15; 73(16):5206-17. PubMed ID: 23786771
    [Abstract] [Full Text] [Related]

  • 13. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor.
    Watson PA, Chen YF, Balbas MD, Wongvipat J, Socci ND, Viale A, Kim K, Sawyers CL.
    Proc Natl Acad Sci U S A; 2010 Sep 28; 107(39):16759-65. PubMed ID: 20823238
    [Abstract] [Full Text] [Related]

  • 14. Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors.
    Zhu Y, Dalrymple SL, Coleman I, Zheng SL, Xu J, Hooper JE, Antonarakis ES, De Marzo AM, Meeker AK, Nelson PS, Isaacs WB, Denmeade SR, Luo J, Brennen WN, Isaacs JT.
    Oncogene; 2020 Nov 28; 39(45):6935-6949. PubMed ID: 32989253
    [Abstract] [Full Text] [Related]

  • 15. Reduced expression of the androgen receptor by third generation of antisense shows antitumor activity in models of prostate cancer.
    Zhang Y, Castaneda S, Dumble M, Wang M, Mileski M, Qu Z, Kim S, Shi V, Kraft P, Gao Y, Pak J, Sapra P, Bandaru R, Zhao H, Vessella RL, Horak ID, Greenberger LM.
    Mol Cancer Ther; 2011 Dec 28; 10(12):2309-19. PubMed ID: 22027692
    [Abstract] [Full Text] [Related]

  • 16. Growth Inhibition by Testosterone in an Androgen Receptor Splice Variant-Driven Prostate Cancer Model.
    Nakata D, Nakayama K, Masaki T, Tanaka A, Kusaka M, Watanabe T.
    Prostate; 2016 Dec 28; 76(16):1536-1545. PubMed ID: 27473672
    [Abstract] [Full Text] [Related]

  • 17. Bruceantin targets HSP90 to overcome resistance to hormone therapy in castration-resistant prostate cancer.
    Moon SJ, Jeong BC, Kim HJ, Lim JE, Kim HJ, Kwon GY, Jackman JA, Kim JH.
    Theranostics; 2021 Dec 28; 11(2):958-973. PubMed ID: 33391515
    [Abstract] [Full Text] [Related]

  • 18. Multimodal actions of the phytochemical sulforaphane suppress both AR and AR-V7 in 22Rv1 cells: Advocating a potent pharmaceutical combination against castration-resistant prostate cancer.
    Khurana N, Kim H, Chandra PK, Talwar S, Sharma P, Abdel-Mageed AB, Sikka SC, Mondal D.
    Oncol Rep; 2017 Nov 28; 38(5):2774-2786. PubMed ID: 28901514
    [Abstract] [Full Text] [Related]

  • 19. Enzalutamide, an androgen receptor signaling inhibitor, induces tumor regression in a mouse model of castration-resistant prostate cancer.
    Guerrero J, Alfaro IE, Gómez F, Protter AA, Bernales S.
    Prostate; 2013 Sep 28; 73(12):1291-305. PubMed ID: 23765603
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.